Table 4.
Registered clinical trials for the treatment of malignant tumors using CRISPR/Cas9 modified adoptive cell therapy. Data from https://clinicaltrials.gov/ (last updated 14/12/2021)
| Clinical Trial Number | Phase | Target Gene | Cancer Type | Cell Type | Sponsor/Country | Recruitment Status |
|---|---|---|---|---|---|---|
| NCT03747965 | Phase 1 | PDCD1-KO | Adult Solid Tumor | Mesothelin-directed CAR-T cells | China | Recruiting |
| NCT03044743 | Phase 1/2 | PDCD1-KO |
Stage IV Gastric Carcinoma Stage IV Nasopharyngeal Carcinoma T-Cell Lymphoma Stage IV Stage IV Adult Hodgkin Lymphoma Stage IV Diffuse Large B-Cell Lymphoma |
EBV-CTL cells | China | Recruiting |
| NCT03081715 | Phase 1 | PDCD1-KO | Esophageal Cancer | Primary T-cells | China | Completed |
| NCT02793856 | Phase 1 | PDCD1-KO | Metastatic Non-small Cell Lung Cancer | Primary T-cells | China | Completed |
| NCT04417764 | Phase 1 | PDCD1-KO | Advanced Hepatocellular Carcinoma | Primary T-cells | China | Recruiting |
| NCT04426669 | Phase 1/2 | CISH-KO |
Gastrointestinal Epithelial Cancer Gastrointestinal Neoplasms Tract Cancer Gastrointestinal Cancer Colo-rectal Cancer Pancreatic Cancer Gall Bladder Cancer Colon Cancer Esophageal Cancer Stomach Cancer |
TILs | The United States | Recruiting |
| NCT03057912 | Phase 1 | CISH-KO | Human Papillomavirus-Related Malignant Neoplasm | TILs | China | Not yet recruiting |
| NCT03399448 | Phase 1 | TRAC, TRBC, PDCD1-KO |
Multiple Myeloma Melanoma Synovial Sarcoma Myxoid/Round Cell Liposarcoma |
NY-ESO-1 redirected autologous T cells | The United States | Completed |
| NCT03545815 | Phase 1 | TRAC, TRBC, PDCD1-KO | Solid Tumor | anti-mesothelin CAR-T cells | China | Recruiting |
| NCT03166878 | Phase 1/2 | TRAC, TRBC, B2M-KO |
B Cell Leukemia B Cell Lymphoma |
UCART019 | China | Recruiting |
| NCT05037669 | Phase 1 | B2M, CIITA, TRAC-KO |
Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma |
CD19-specific CAR-T cells | The United States | Not yet recruiting |
| NCT04037566 | Phase 1 | HPK1-KO |
Acute Lymphoblastic Leukemia in Relapse Acute Lymphoblastic Leukemia Refractory Lymphoma, B-Cell CD19 Positive |
XYF19 CAR-T cells | China | Recruiting |
| NCT04557436 | Phase 1 | CD52 and TRAC-KO | B Cell Acute Lymphoblastic Leukemia | CD19-specific CAR-T cells | The United Kingdom | Recruiting |
| NCT04976218 | Phase 1 | TGFβR-KO | Advanced Biliary Tract Cancer | CAR-EGFR T cells | Unknown | Not yet recruiting |
| NCT04767308 | Early Phase 1 | CD5-KO |
CD5+ Relapsed/Refractory Hematopoietic Malignancies Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Diffuse Large B-cell Lymphoma Follicular Lymphoma Peripheral T-cell Lymphomas |
CT125A cells | Unknown | Not yet recruiting |
| NCT04244656 | Phase 1 | Unknown | Multiple Myeloma | Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) | The United States | Recruiting |
| NCT04438083 | Phase 1 | Unknown | Renal Cell Carcinoma | Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) |
The United States Australia Canada Netherlands |
Recruiting |
| NCT04502446 | Phase 1 | Unknown | T Cell Lymphoma | Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) |
The United States Australia Canada |
Recruiting |
| NCT04035434 | Phase 1 | Unknown |
B-cell Malignancy Non-Hodgkin Lymphoma B-cell Lymphoma Adult B Cell Acute Lymphoblastic Leukemia |
CD19-specific CAR-T cells (CTX110) |
The United States Australia Canada Germany Spain |
Recruiting |
| NCT04637763 | Phase 1 | Unknown |
Lymphoma Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma |
CD19-specific CAR-T cells (CB-010) | The United States | Recruiting |
| NCT03398967 | Phase 1/2 | Unknown |
B Cell Leukemia B Cell Lymphoma |
Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells | China | Recruiting |
| NCT05066165 | Phase 1/2 | Unknown | Acute Myeloid Leukemia | WT1-directed TCR T cells |
The United States The United Kingdom |
Not yet recruiting |
| NCT04244656 | Phase 1 | Unknown | Multiple Myeloma | Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) |
The United States Australia Canada Spain |
Recruiting |